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Abstract
Purpose The objective of this randomized controlled trial was
to assess the additional effect of a chest-worn sleep position
trainer (SPT) in patients with residual supine-dependent ob-
structive sleep apnea (sdOSA) under mandibular advance-
ment device (MAD) therapy.
Methods Baseline and follow-up polysomnography with
MAD were performed. Twenty patients with sdOSA under
MAD therapy underwent two consecutive randomized
polysomnographies: one with SPT and one with combination
of SPT + MAD. Data are presented as median (quartile 1,
quartile 3).
Results The SPT reduced the time spent in supine sleeping
position compared to baseline and MAD therapy. Both MAD
and SPT were individually effective in reducing the overall
apnea/hypopnea index (AHI) significantly when compared to
baseline from 20.8 (15.1; 33.6)/h at baseline to 11.0 (6.7;
13.8)/h and to 11.1 (3.5; 17.7)/h with MAD or SPT, respec-
tively. The combination of SPT + MAD further reduced the
overall AHI to 5.7 (3.6; 7.4), which was significantly lower
than with MAD alone (p<0.001) and SPT alone (p<0.008),
respectively.
Conclusions The results of this study indicate that combina-
tion of SPT + MAD leads to a higher therapeutic efficacy in
patients with sdOSA under MAD therapy when compared to
one of the treatment modalities alone.
Keywords Obstructive sleep apnea/hypopnea syndrome .
Sleep-disordered breathing . Supine-dependent
Introduction
Approximately 50–60 % of patients with obstructive sleep
apnea (OSA) suffer from supine-dependent OSA (sdOSA)
defined according to Cartwright [1] as having twice as many
respiratory events in the supine sleeping position compared to
the non-supine sleeping position. Mador et al. [2] defined
sdOSA as having twice as many respiratory events in the
supine position than in non-supine positions along with an
apnea/hypopnea index (AHI) <5 events/h in the non-supine
position and a 15-min threshold for sleep in supine and non-
supine position. A third definition of sdOSA was introduced
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byMarklund et al. [3, 4] defined as a supine AHI ≥10 events/h
together with a non-supine AHI of <10 events/h.
Positional therapy is a treatment modality aimed at
preventing sleep in the supine position [5]. It is recently
shown during drug-induced sleep endoscopy (DISE) that
a change of body position from supine to lateral position
leads to improvement of upper airway collapse in patients
with sdOSA [6]. In the future, DISE could be performed
in both the supine and lateral positions [7]. The most
widely used technique to avoid the supine sleeping
position involves strapping a bulky object to the back of
the patient thereby preventing supine positioning. Several
studies have shown that such therapies have a significant
positive effect on snoring and OSA severity in patients
with sdOSA [5, 8–12]. However, the bulky object is
uncomfortable for patients and results in disturbed sleep
and low long-term compliance rates [8, 9]. Therefore,
positional therapy has not found its way into daily OSA
treatment routine to date [13]. In order to overcome such
compliance problems, both a new neck-worn device and a
chest-worn device correcting the supine sleeping position
by activating a vibration alarm were evaluated. This novel
concept of positional therapy showed promising results in
reducing apnea severity, together with a higher compli-
ance [14, 15].
Oral appliance therapy is a non-invasive treatment for
patients with snoring and OSA [16]. The most common type
of oral appliances prescribed for the treatment of OSA is the
mandibular advancement device (MAD) worn intraorally at
night in order to reduce upper airway collapse by protruding
the mandible [4, 17–19]. This treatment modality, although
not as effective as continuous positive airway pressure
(CPAP) in reducing apnea severity, is preferred by the major-
ity of patients and has a relatively high objective compliance
rate [20–22].
In a recent study, it was found that up to 34 % of patients
treated with MAD therapy showed sdOSA under MAD ther-
apy [23]. Our research hypothesis is that those patients could
benefit from additional positional therapy.
The aim of this prospective randomized controlled trial
(RCT) was to investigate the feasibility of the additional use
of a chest-worn sleep position trainer (SPT) in patients with
sdOSA under MAD therapy.
Material and methods
Participants, setting, and study design
In Belgium, CPAP is the standard treatment for patients with
moderate to severe OSA (AHI >20 events/h) and is fully
reimbursed in these patients. Therefore, our policy is to pro-
pose a trial of CPAP therapy to any patient with an AHI of at
least 20 events/h. In our multidisciplinary setting, patients
with mild OSA (AHI <20 events/h) and patients with CPAP
intolerance are referred to the multidisciplinary dental sleep
clinic involved in the decision-making for the implementation
of MAD therapy [24].
Twenty patients with a residual sdOSA (AHI ≥5/h) follow-
ing both Cartwright’s [5] and Marklund’s [3, 4] criteria under
MAD therapy were randomly selected out of our patient
population. At the start of MAD therapy, patients were not
judged suitable for MAD treatment if they suffered from any
pre-existing active temporomandibular joint dysfunction, if
their dental status or periodontal health precluded them from
wearing an oral appliance, or if theywere fully edentulous [25,
26]. In addition, patients with other sleep disturbances than
sleep-related breathing disorders were excluded from the
study.
The patients were invited to participate in this RCT design
in which two treatment modalities were tested in a randomized
order: the SPT and combination of SPT + MAD therapy. The
other inclusion criteria were ≥20 % of total sleep time spent in
the supine position during polysomnography (PSG) with
MAD and unchanged body mass index (BMI±1 kg/m2)
between diagnostic PSG and inclusion in the study.
Seven patients had a baseline AHI <20 events/h and were
therefore CPAP naive. CPAP therapy was offered in the other
13 patients: 10 of them could not tolerate the CPAP device,
two patients refused to start CPAP therapy, and one patient
wanted an alternative for CPAP. The study design includ-
ed a baseline level I PSG and a follow-up PSG with the
MAD in situ. These PSGs were performed in routine
clinical practice to assess the therapeutic efficacy of the
MAD.
Patients were randomly allocated in a 1:1 ratio to be treated
with either the SPT prior to combination therapy or combina-
tion therapy prior to the SPT, see Fig. 1. At the end of the
study, but before knowing the results of the consecutive study
nights during the RCT, patients were asked to fill out a
questionnaire about their personal therapy preference (MAD,
SPT, or combination of SPT + MAD).
The reported trial was conducted in accordance with the
institutional guidelines of the ethical committee (Belgian reg-
istration number: B300201212947) and informed consent was
obtained. The trial was registered at clinicaltrials.gov
(NCT01535521).
Oral appliance
Patients were treated with a custom-made, titratable MAD
(Respident Butterfly, Dormoco, Nijlen, Belgium (n=14) or
SomnoDent Flex, Somnomed AG, Australia (n=6)). After
receiving full explanation of the titration procedure, patients
were instructed to gradually titrate the MAD until subjective
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resolution of symptoms occurred or until the maximum com-
fortable limit was reached.
Sleep position trainer
A chest-worn SPT placed at the level of the sternum was used
in this study (NightBalance™, Delft, The Netherlands)
(Fig. 2) [14]. The SPT is a small, lightweight device (72×
35×10 mm, 25 g) that allows for body position changes
during sleep without any movement restrictions. The device
continuously monitors position, providing a vibration stimu-
lus when in supine position. The vibration is variable in
frequency and gradually increases in amplitude and duration
until the patient shifts to a non-supine position (Fig. 2).
Polysomnographic outcome measures
One individual who was blinded for the treatment assignment
scored the polysomnographic evaluations. The severity of
OSAwas expressed by the overall AHI, defined as the average
number of apneas and hypopneas per hour of sleep. The
supine and non-supine AHIs were defined as the average
number of apneas and hypopneas per hour of sleep occurring
in the supine and non-supine position, respectively. The posi-
tional change index was defined as the total number of posi-
tional changes during sleep per hour of total sleep time [27].
Treatment response was defined as a reduction in overall AHI
under therapy of ≥50 % compared to baseline. Another
success criterion used in this study was a reduction in
overall AHI of ≥50 % compared to baseline combined
with a post-treatment AHI of <5 events/h.
Statistical analysis
Data were statistically analyzed using SPSS software (SPSS
version 21, Statistical Package for Social Sciences, SPSS Inc.,
Chicago, Illinois, USA). A power calculation revealed that
with 20 patients, a power of 80 % with an effect size of 0.7
could be achieved at a significance level of 5 %.
The nonparametric Wilcoxon-signed rank test for paired
observations was performed to compare different variables
among the different study nights. Bonferroni correction for
multiple comparisons was performed when comparing the
results of the four different study nights. The significance
Fig. 1 Flow chart of the study
design
Fig. 2 The sleep position trainer
used in this study
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level was set at p<0.05, and the corrected significance level
was p<0.008. The McNemar test was performed to compare
the success rates of the different study nights. Since the data
were not normally distributed, data are expressed as median
values and their lower and upper quartiles (Q1, Q3).
Results
Subjects
Twenty patients with sdOSA under MAD therapy (age, 52±
11 years; male/female, 11/8; overall AHI, 24.6±10.2/h; body
mass index (BMI), 26.4±3.0 kg/m2) were included in this
RCT, see Table 1 for the baseline characteristics. There was
no significant difference in age, weight, or sleep apnea sever-
ity between the two randomized groups. Four patients (21 %)
were non-supine-dependent at baseline according to
Cartwright’s definition, but all of them became supine-
dependent under MAD therapy.
There was one patient who suffered from non-apneic snor-
ing at baseline and was excluded from further analysis.
Time spent in supine sleeping position
Figure 3 shows the percentages of total sleep time spent in
supine position during the four study nights: baseline, with
MAD, with SPT, and with combination of SPT + MAD
therapy. The SPT was found to be effective in reducing
the time spent in supine position compared to baseline
from 31.9 (15.4; 52.4)% at baseline to 0.0 (0.0; 1.1)%
with SPT (p=0.001).
In addition, the time spent in supine position was reduced
with the SPT compared to MAD therapy, from 49.5 (32.6;
48.9)% with MAD to 0.0 (0.0; 1.1)% with SPT (p<0.001),
respectively. The time spent in the supine position with SPT +
MAD therapy was 0.0 (0.0; 1.0)% and was significantly lower
compared to baseline (p=0.001) or MAD therapy alone
(p<0.001).
Positional change index
The frequency of positional changes was similar between the
different study nights. The positional change index at baseline
was 2.0 (1.6; 2.8)/h, which was not significantly different
from the positional change index during MAD therapy [1.7
(1.2; 2.4)/h], SPT therapy [2.2 (1.6; 3.0)/h], or combination
therapy [2.4 (1.7; 3.4)/h].
Polysomnographic efficacy
The polysomnographic results of respiratory disturbances and
sleep quality for the different study nights are shown in
Table 2.
Respiratory disturbances
There was a significant difference in overall AHI between the
four conditions tested, as graphically illustrated in Fig. 4. Both
MAD and SPT were individually effective in reducing the
median overall AHI significantly when compared to baseline,
from 20.9 (17.0; 34.0)/h to 11.0 (6.6; 14.0)/h and to 21.8 (3.9;
17.9)/h, respectively. Combination SPT + MAD therapy fur-
ther reduced the median overall AHI to 5.5 (3.4; 7.2)/h. This
was significantly lower when compared to baseline
(p<0.001), MAD alone (p<0.001) and SPT alone (p<0.008).
The supine AHI was reduced effectively with MAD when
compared to baseline, from 39.1 (26.4; 58.2)/h to 21.8 (14.8;
29.5)/h. In addition, the SPT further reduced the supine AHI
significantly when compared toMAD therapy to a supineAHI
of 0.0 (0.0; 11.5)/h.
In contrast to the SPT, MAD therapy was effective in
reducing the non-supine AHI values when compared to base-
line. Moreover, the non-supine AHI values with combination
SPT +MAD therapy were significantly lower when compared
to both baseline and SPT and comparable to that of the MAD
alone.
Table 1 Baseline characteristics of the study population
Parameter Mean±SD
Age (years) 52.5±10.5
Gender 57.9 % male
Body mass index, BMI (kg/m2) 26.4±3.0
Overall apnea/hypopnea index, AHI (events/h) 20.9 (17.0; 34.0)
Supine AHI (events/h) 39.1 (26.4; 58.2)
Non-supine AHI (events/h) 11.1 (6.3; 26.1)
Data are expressed as mean±standard deviation (SD), percentages or
median (Q1; Q3)
Fig. 3 Percentages of total sleep time spent (TST) in the supine position
for the different study nights
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Sleep quality
Total sleep time, sleep efficiency, and percentage of stage 1,
stage 2, and REM sleep did not differ significantly between
the different study nights (Table 2). There was a significant
increase in stage 3 sleep withMAD compared to baseline. The
arousal index increased significantly with SPT when com-
pared to MAD therapy (p<0.008) and combination SPT +
MAD therapy (p<0.008) but not when compared to baseline.
However, there was a decrease in the percentage of arousals
associated with respiratory events during PSGs with MAD
alone, SPT alone, and combination SPT +MAD therapy from
35.4 (24.8; 59.4)% at baseline to 17.1 (7.0; 32.0)%, 19.6 (4.7;
32.3)%, and 8.9 (2.9; 12.9)%, respectively. The percentage of
arousals associated with respiratory events was the lowest
during combination SPT + MAD therapy.
Table 2 Polysomnographic results of the different study nights
Parameter Baseline With MAD With SPT With SPT + MAD
Overall AHI (events/h) 20.9 (17.0; 34.0) 11.0 (6.6; 14.0)* 12.8 (3.9; 17.9)* 5.5 (3.4; 7.2)*,$,∞
Supine AHI (events/h) 39.1 (26.4; 58.2) 21.8 (14.8; 29.5)* 0.0 (0.0; 11.5)*,$ 0.0 (0.0; 22.7)*
Non-supine AHI (events/h) 11.1 (6.3; 26.1) 3.9 (2.0; 5.0)* 12.8 (3.8; 17.2)$ 4.8 (2.0; 6.0)*,∞
ODI (events/h) 7.7 (6.6; 16.5) 3.8 (1.2; 5.5)* 2.6 (1.0; 4.6)* 1.8 (1.0; 3.0)*,$
Mean SaO2 (%) 94.9 (93.6; 95.8) 94.8 (93.8; 96.2) 95.3 (94.0; 96.2) 95.4 (94.1; 96.9)
Min SaO2 (%) 84.7 (79.0; 86.0) 87.0 (84.0; 91.0) 88.0 (84.0; 90.0)* 89.0 (87.0; 91.0)*
TST (min) 394.5 (361.2; 420.6) 419.0 (407.0; 452.5) 405.5 (386.5; 438.2) 413.0 (385.0; 444.2)
Sleep efficiency (%) 85.1 (79.4; 87.2) 87.5 (82.4; 92.6) 84.6 (80.6; 87.9) 84.2 (79.0; 89.7)
Stage N1 (% TST) 5.8 (3.4; 6.7) 3.9 (3.2; 5.6) 4.4 (3.3; 6.2) 4.1 (3.1; 4.9)
Stage N2 (% TST) 51.4 (38.7; 54.6) 47.9 (43.5; 51.0) 48.7 (48.0; 51.2) 46.6 (39.0; 50.2)
Stage N3 (% TST) 11.9 (5.9; 18.9) 20.0 (15.3; 22.8)* 15.2 (12.3; 18.9) 17.6 (11.4; 22.7)
Stage REM (% TST) 17.3 (13.7; 21.3) 21.2 (15.3; 26.2) 20.5 (15.6; 26.1) 20.5 (19.1; 27.7)
Arousal index (events/h) 10.1 (6.6; 15.0) 9.2 (7.3; 14.7) 19.5 (11.2; 24.3)$ 11.7 (6.7; 13.6)∞
Percentage of respiratory arousals (%) 35.4 (24.8; 59.4) 17.1 (7.0; 32.0)* 19.6 (4.7; 32.3)* 8.0 (2.9; 12.9)*,$
Number of awakenings 22.0 (13.0; 29.0) 17.0 (13.3; 21.5) 21.5 (14.5; 30.0) 18.0 (13.3; 24.8)
Percentage of TST in supine position (%) 31.9 (15.4; 52.4) 49.5 (32.6; 48.9) 0.0 (0.0; 1.1)*,$ 0.0 (0.0; 1.0)*,$
Positional change index (changes/h) 2.0 (1.6; 2.8) 1.7 (1.2; 2.4) 2.2 (1.6; 3.0) 2.4 (1.7; 3.4)
Data are presented as median (Q1, Q3)
AHI apnea/hypopnea index, ODI oxygen desaturation index, TST total sleep time, REM rapid eye movement
*Statistically significant (p<0.008) as compared to baseline
$ Statistically significant (p<0.008) as compared to PSG with MAD
∞Statistically significant (p<0.008) as compared to PSG with SPT
Fig. 4 Overall apnea/hypopnea index (AHI) for the different conditions
tested. The different gray scales represent the varying levels of sleep
apnea severity, ranging from normal nocturnal breathing (AHI <5/h
sleep), mild OSA (AHI 5–15/h), moderate OSA (AHI 15–30/h), to severe
OSA (AHI >30/h). Left panel: Box plots for the four different study
nights. The 75th and 25th percentiles are represented by the upper and
lower margins, the mean values by the closed dots, and the median values
by the horizontal line. Whiskers represent the maximum value (top) and
the minimum value (bottom) of the dataset. Outliers are represented by an
open dot. Right panel: The individual patient data for the different study
nights are plotted in line graphs
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Treatment outcome
Overall, treatment response rate (≥50 % reduction in overall
AHI when compared to baseline) was significantly higher
with combination of SPT + MAD (95 %) when compared to
MAD alone (45 %; p<0.01) or SPT alone (55 %; p<0.01).
While using success defined as a reduction in overall AHI of
≥50 % compared to baseline combined with a post-treatment
AHI of <5 events/h, the success rates were 0, 25, and 35 %,
respectively for MAD alone, SPT alone, or combination of
SPT + MAD.
Subjective preference of therapy
Fifteen patients filled out the subjective questionnaire. Four
patients identified MAD therapy as their subjective treatment
of choice, four patients preferred SPT, and seven patients
preferred the combination of SPT + MAD.
Discussion
This prospective RCT was the first to evaluate the feasibility
and the efficacy of an additional chest-worn SPT in patients
whowere unsuccessfully treated withMAD therapy due to the
presence of sdOSA under MAD therapy. The results indicate
that the SPT used in this study significantly reduced the time
spent in the supine position when compared to baseline or
MAD therapy. Furthermore, both MAD and SPT were indi-
vidually effective in reducing the apnea severity in patients
with sdOSA under MAD therapy. In addition, combination
SPT + MAD therapy leads to a higher therapeutic efficacy in
patients with sdOSA under MAD therapy when compared to
one of the treatment modalities alone.
It is reported in literature that a treatment modality for OSA
that is not able to completely eliminate all breathing abnor-
malities leaves the patient with a residual OSA although often
less severe than the initial OSA. Therefore, the residual OSA
is probably more supine-dependent since supine-dependent
OSA is more frequently seen in mild OSA. In a previous
study, it was described that one third of patients under MAD
therapy have a residual sdOSA. It was hypothesized that these
patients with residual sdOSA under MAD therapy could
benefit from additive therapy with SPT.
Most of the included patients (80 %) were also supine-
dependent at baseline. In those patients, monotherapy with
SPT should be considered as a first treatment option.
However, in the past, most of the positional therapies had
low acceptance and compliance due to the bulkiness of the
devices and, therefore, was not frequently prescribed as a
therapeutic option. Recently, the technology of positional
therapy has been improved, with promising results.
Additionally, our results showed that the success rate of SPT
alone was up to 55 %. The most promising results were
achieved with combination SPT +MAD therapy, with success
rates up to 95 %.
In the present study, 95 % of patients were responders to
combination SPT + MAD therapy based on success criteria
defined as a reduction in overall AHI of ≥50 % according to
literature [28]. MAD therapy was effective in reducing both
supine AHI and non-supine AHI when compared to baseline
(Table 2). This indicates that MAD therapy, aimed at increas-
ing the cross-sectional upper airway volume by advancing the
mandible, has an effect on both non-supine AHI and supine
AHI. On the other hand, the mode of action of the SPT is
preventing the patients from the supine sleeping position. The
results show that the time spent in supine position decreased
dramatically with the SPT. In some patients, the AHI supine
remained still high showing that these patients still have a
problem when sleeping in the supine position, but with reduc-
ing the time spent in the supine position, the sleep apnea
severity decreased in those patients.
The arousals caused by the SPT alone were significantly
higher than those by the MAD alone or combination therapy.
In addition, the percentage of arousals associated with respi-
ratory events decreased during the study nights with MAD
therapy, SPT, and combination SPT + MAD therapy. This
indicates that the SPT is associated with an increase in
arousals when compared to baseline or MAD therapy, espe-
cially those arousals not associated with respiratory events
were increased. In future studies, synchronization of the time-
line of the SPT with that of the PSG could be of additional
interest in order to determine whether or not the arousals are
associated with the vibration alarm of the SPT that forces the
patient to change body position. In two other studies, one short
term (28 days) [14] and one long term (6 months) [29],
patients followed a training program to get used to the SPT
after which no differences in arousal index were found be-
tween baseline and with SPT.
To date, only one paper has been published comparing the
efficacy of an oral appliance and positional therapy [5]. In that
study, Cartwright et al. [5] described the efficacy of combina-
tion therapy of a posture alarm giving an auditory beep when
in supine position and a tongue retaining device (TRD), an
oral appliance that holds the tongue in a forward position.
Patients were assigned to either therapy with the posture
alarm, the TRD, or combination therapy with the posture
alarm and the TRD. The results of the present RCT are in
accordance with the results of Cartwright et al. suggesting that
the combination of an oral appliance and positional therapy is
better than one of the treatment modalities alone.
Recently, a new classification system for sdOSAwas pro-
posed, the Amsterdam Positional OSA Classification
(APOC), to classify patients in either true sdOSA patients
who could be cured by PT alone or in patients who showed
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benefit from PT but could not be cured and therefore would
benefit from combination of therapies [30].
The present study has its limitations. First, a relatively
small number of patients was included in this prospective
RCT. However, the present study was a proof of concept to
evaluate the possible application and first results of this spe-
cific combination therapy. Second, the present study did not
incorporate an SPT training program, allowing the patients to
gradually get used to avoid the supine sleeping position [14].
Third, the MAD was titrated upon subjective resolution of
symptoms or until reaching the maximum comfortable limit.
The patients selected for this study were treated unsuccessful-
ly and could have needed additional mandibular advance-
ment. However, there was a clear residual sdOSA under
MAD therapy. These patients could therefore benefit from
additional PT in combination with the MAD instead of further
titrating the MAD. Further titration of the MAD includes a
risk of more side-effects due to the more advanced mandible.
Finally, compliance was not taken into account since the
patients were using the SPT the whole night. However, the
SPT used in this study includes a feature for measuring com-
pliance objectively, showing a compliance rate at 6-month
follow-up of 64.4 % in another study [29].
Despite the limitations, the authors stress the clinical rele-
vance of the results of this prospective RCT. In the past, it has
been shown that up to one third of patients treated with MAD
therapy have sdOSA under therapy [23]. The results of the
present study indicate that a combination of SPT + MAD
therapy further reduces the sleep apnea severity when com-
pared to the individual treatment modalities. In addition, the
success rate with combination therapy increased by up to 65%
points when compared to MAD therapy alone. These findings
suggest that when patients are unsuccessfully treated with
MAD therapy, the presence of sdOSA should be checked
and combination SPT + MAD therapy could be suggested in
eligible patients. However, further clinical trials are required
to assess the applicability, the therapeutic efficacy, and com-
pliance rates at long-term follow-up with this combination
therapy, and with other possible combination therapies such
as SPT + CPAP therapy.
Conclusions
The results of this prospective randomized controlled trial
indicate that the SPT used in this study significantly reduced
the time spent in the supine position compared to baseline or
MAD therapy. In patients with sdOSA under MAD therapy,
both MAD therapy and SPT were individually effective in
reducing AHI. However, combination SPT + MAD therapy
further reduced the sleep apnea severity and leads to a signif-
icantly higher OSA alleviation in patients with sdOSA under
MAD therapy.
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